Insulin alpha-chain (1-13) is a human leucocyte antigen (HLA)-DR4-restricted epitope comprising the first 13 amino acids of the insulin A-chain.
Insulin alpha-chain 1-13 is a synthetic peptide fragment corresponding to the N-terminal residues 1 through 13 of the insulin A-chain. As a defined segment of the insulin molecule, this peptide is widely valued in biochemical research for its role in elucidating the structural and functional properties of insulin and its derivatives. The alpha-chain region is essential to the native conformation and biological activity of insulin, making this peptide fragment a foundational tool in studies of protein folding, receptor interactions, and epitope mapping. Its defined sequence and structural features enable researchers to dissect the contributions of specific residues to the overall function and stability of insulin, facilitating a range of experimental applications in peptide science and endocrinology.
Peptide structure-function analysis: The 1-13 fragment of the insulin A-chain is frequently employed in studies aimed at understanding the relationship between primary sequence and higher-order structure in insulin. By isolating this segment, researchers can investigate how the N-terminal region contributes to the folding and stability of the full-length hormone. Experiments utilizing this peptide can reveal insights into disulfide bond formation, alpha-helical propensity, and the role of individual amino acids in maintaining the functional conformation of insulin. Such analyses are critical for mapping structure-activity relationships and informing rational design of insulin analogs.
Epitope mapping and immunological studies: The defined sequence of the insulin alpha-chain 1-13 peptide makes it a valuable tool for identifying antigenic determinants recognized by anti-insulin antibodies. Researchers use this fragment in immunoassays, such as ELISA or Western blotting, to pinpoint specific epitopes within the insulin molecule that elicit immune responses. This application is instrumental in advancing the understanding of autoimmune recognition in conditions like type 1 diabetes, as well as in the development and validation of antibody-based detection methods for insulin and its analogs.
Peptide synthesis and modification research: As a representative insulin-derived peptide, the alpha-chain 1-13 fragment serves as a model substrate for developing and optimizing peptide synthesis methodologies. Its moderate length and well-characterized sequence make it suitable for testing new solid-phase peptide synthesis strategies, evaluating coupling reagents, and exploring post-synthetic modifications such as labeling or cyclization. Successful synthesis and purification of this peptide provide benchmarks for quality control and scalability in peptide manufacturing workflows.
Receptor binding and interaction assays: The N-terminal region of the insulin A-chain is implicated in interactions with the insulin receptor and other binding partners. Researchers utilize the 1-13 peptide fragment in binding assays to assess its affinity for receptor domains or to map contact points critical for hormone-receptor engagement. These experiments contribute to a deeper understanding of the molecular determinants of insulin action and can inform the engineering of peptides with tailored receptor selectivity or altered biological profiles for research use.
Proteolytic processing and degradation studies: The insulin alpha-chain 1-13 peptide is also employed in investigations of proteolytic cleavage and peptide stability. By exposing this fragment to various proteases or cellular extracts, scientists can monitor degradation patterns, identify cleavage sites, and evaluate the resistance of the peptide to enzymatic breakdown. Such studies provide valuable information on the metabolic fate of insulin-derived peptides and support the development of strategies to enhance peptide stability for research and analytical applications.
1. TMEM16F and dynamins control expansive plasma membrane reservoirs
3. Low bone turnover and low BMD in Down syndrome: effect of intermittent PTH treatment
4. Myotropic activity of allatostatins in tenebrionid beetles
5. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More